- not yet recruiting
VOLta Medical AI-software in REal-World During AF Ablation
This study looks at how well a new AI software, Volta AF-Xplorer II, works during a heart procedure called a catheter ablation for atrial fibrillation. We want to see how safe and effective it is in real-life practice over two years.
France - recruiting
Clinical Cohort Study - TRUST
The TRUST study is looking at heart rhythm problems like atrial fibrillation. It aims to understand how different treatments work over time for people in Hamburg, Germany. Researchers will collect information and samples to learn more about these conditions and improve care.
Germany - recruitingNA
Relevance of Recording an ECG Trace With a Connected Watch
This study looks at how well smartwatches can record heart activity. Researchers are comparing smartwatch ECGs with standard hospital ECGs in people with healthy hearts and those with heart rhythm problems, including children, to see how accurate smartwatches are.
France - active not recruiting
Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation
This study looks at how well a new AI software, Volta Medical AI, helps doctors treat an irregular heartbeat called atrial fibrillation (AF) using a procedure called ablation. It checks patient safety, how well the treatment works long-term, and the costs involved in real-life hospital settings.
France · Germany - recruiting
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
This study looks at how well certain medical devices work for people with heart rhythm problems when they're used in normal hospital care. It helps doctors understand more about these devices and how they help patients.
Austria · Belgium · Denmark - recruitingNA
Ablation of Focal Activation in Atrial Fibrillation
This study investigates if a new mapping technique, RETRO-Mapping, can accurately find specific electrical 'drivers' of persistent atrial fibrillation (AF). We aim to see if treating these drivers, in addition to standard treatment, improves outcomes for people living with persistent AF.
United Kingdom